Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1733648 10.3389/fphar.2025.1733648 Correction Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment Cummings et al. 10.3389/fphar.2025.1733648 Cummings Jason E. 1 † Project administration Data curation Writing - review and editing Investigation Writing - original draft Formal Analysis Woolhiser Lisa K. 1 † Investigation Data curation Conceptualization Methodology Writing - review and editing Formal Analysis Guglielmi Vincent 1 Writing - review and editing Investigation Wernsman Machenzie 1 Writing - review and editing Investigation Romano Ashley 1 Writing - review and editing Investigation Pauly Samantha 2 3 Writing - review and editing Investigation Belisle John T. 1 Formal Analysis Writing - review and editing Supervision Walter Nicholas D. 2 3 4 Investigation Conceptualization Writing - review and editing Methodology Supervision Data curation Project administration Writing - original draft Robertson Gregory T. 1 2 Writing - original draft Writing - review and editing Formal Analysis Visualization Supervision Methodology Data curation Conceptualization Investigation Slayden Richard A. 1 * Writing - original draft Formal Analysis Resources Project administration Visualization Data curation Validation Writing - review and editing Supervision Conceptualization Software Funding acquisition Investigation Methodology Mycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States Consortium for Applied Microbial Metrics, Aurora, CO, United States Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States Rocky Mountain Regional VA Medical Center, Aurora, CO, United States Correspondence: Richard A. Slayden, richard.slayden@colostate.edu

These authors have contributed equally to this work

 18 11 2025 2025 16 1733648 27 10 2025 28 10 2025 Copyright © 2025 Cummings, Woolhiser, Guglielmi, Wernsman, Romano, Pauly, Belisle, Walter, Robertson and Slayden. 2025 Cummings, Woolhiser, Guglielmi, Wernsman, Romano, Pauly, Belisle, Walter, Robertson and Slayden https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment by Cummings JE, Woolhiser LK, Guglielmi V, Wernsman M, Romano A, Pauly S, Belisle JT, Walter ND, Robertson GT and Slayden RA (2025). Front. Pharmacol. 16:1667592. doi: 10.3389/fphar.2025.1667592 high-burden aerosol BALB/c model high burden tuberculosis mycobacteria drug discovery section-in-acceptance Experimental Pharmacology and Drug Discovery

There was a mistake in Figure 1 as published. Figure S1 was published in place of the true Figure 1. The corrected Figure 1 appears below.

Study design for evaluating treatment duration-dependent responses to standard HRZE therapy in a murine model of Mycobacterium tuberculosis infection. Mice were aerosol-infected with M. tuberculosis on Day−11 and one group was sacrificed at Day 1 post-infection to establish baseline lung bacterial burden. All remaining animals remained untreated until Day 0, at which point treatment (Tx) was initiated. Groups received treatment for 2, 4, or 8 weeks, with corresponding sacrifices on Days 12, 26, and 54 to assess treatment efficacy. Endpoints included colony-forming unit (CFU) enumeration and determination of RS Ratio. Day 54 mice were also evaluated for histopathological changes and PK analysis. A parallel untreated control group was maintained through the full 8-week period.

Study design for evaluating treatment duration-dependent responses to standard HRZE therapy in a murine model of Mycobacterium tuberculosis infection. Mice were aerosol-infected with M. tuberculosis on Day–11 and one group was sacri!ced at Day 1 post-infection to establish baseline lung bacterial burden. All remaining animals remained untreated until Day 0, at which point treatment (Tx) was initiated. Groups received treatment for 2, 4, or 8 weeks, with corresponding sacri!ces on Days 12, 26, and 54 to assess treatment ef!cacy. Endpoints included colony-forming unit (CFU) enumeration and determination of RS Ratio. Day 54 mice were also evaluated for histopathological changes and PK analysis.

Supplemental material Figure S1 was omitted. The file has now been published.

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland